Lamberts et al. used [89Zr]Zr-MMOT0530A, an anti-MSLN antibody, in 11 cancer patients (7 with pancreatic cancer and 4 with ovarian cancer) and observed enhanced tumor uptake in at least one tumor lesion in all the patients, as well as heterogeneity in tumor uptake between and within patients [64]. The gene discussed is MSLN; the disease is neoplasm.